|1.||Batt, David: 2 articles (09/2007 - 03/2006)|
|2.||Wickman, Sarah: 1 article (09/2007)|
|3.||Fee, Brian E: 1 article (09/2007)|
|4.||Hjelmeland, Anita B: 1 article (09/2007)|
|5.||Lattimore, Kathryn P: 1 article (09/2007)|
|6.||Rich, Jeremy N: 1 article (09/2007)|
|7.||Shi, Qing: 1 article (09/2007)|
|8.||Keir, Stephen T: 1 article (09/2007)|
|9.||Bigner, Darell D: 1 article (09/2007)|
|10.||Friedman, Henry S: 1 article (09/2007)|
09/01/2007 - "Furthermore, LBT613 and RAD001 in combination synergized to decrease glioma cell proliferation in association with G(1) cell cycle arrest. "
09/01/2007 - "Treatment with either LBT613 or RAD001 alone significantly decreased the proliferation of multiple human glioma cell lines. "
09/01/2007 - "To determine if targeting RAF and TOR activities could result in decreased protumorigenic glioma cellular behaviors, we evaluated the abilities of LBT613 and RAD001 to affect the proliferation, migration, and invasion of human glioma cells. "
09/01/2007 - "LBT613 decreased phosphorylation of extracellular signal-regulated kinase 1 and 2, downstream effectors of RAF, in a human glioma cell line. "
09/01/2007 - "These data suggest that the combination of LBT613 and RAD001 reduces glioma cell proliferation and invasion and support examination of the combination of RAF and TOR inhibitors for the treatment of human glioblastoma patients."
|3.||Glioblastoma (Glioblastoma Multiforme)
|1.||Mitogen-Activated Protein Kinase 3
|1.||Heterologous Transplantation (Xenotransplantation)